Addendum
Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53
Report documents
-
Addendum
Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53
Dossier assessment
Indication:
Adult patients with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after complete resection
Result of dossier assessment:
Unchanged after addendum:
- Patients who are eligible for cisplatin-containing therapy for adjuvant treatment: added benefit not proven
- Patients who are not eligible for cisplatin-containing therapy for adjuvant treatment: hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.
Project details
- Project no.
- A22-97
- Commission
- Commission awarded on 06.09.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed